Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD
A Phase 2a trial is assessing frexalimab, brivekimig, and rilzabrutinib for reducing proteinuria in FSGS and MCD. Primary outcome is the percent reduction in urine protein to creatinine ratio (UPCR).
Researchers are studying three new drugs to see how well they reduce protein in urine for patients with certain kidney diseases. The study aims to find out if these drugs can help patients feel better…
Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria
A Phase 2 trial is evaluating ManNAc for primary FSGS in 30 patients. Primary endpoints include proteinuria reduction and safety. Results pending.
Researchers are testing a new drug called ManNAc for people with a kidney disease that causes protein loss. The study aims to see if this drug can safely reduce protein in urine and improve kidney hea…